The metabolism and mode of action of penciclovir [9-(4-hydroxy-3-hydroxymethylbut-1-yl) Penciclovir, through its triphosphate ester (Fig. 1) , is a potent and selective antiherpesvirus agent, particularly against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2, respectively) and varicella-zoster virus (VZV) (9, 3, 4). Previous studies (3, 4, 9) showed that penciclovir has a spectrum of antiviral activity similar to that of acyclovir, but that penciclovir has an antiviral effect that is longer lasting than that of acyclovir. This may relate to the efficient trapping of the active metabolite, the triphosphate ester of penciclovir, within virus-infected cells (22). Penciclovir and its well-absorbed oral form, famciclovir (23), are undergoing clinical trials for their efficacies not only against HSV-1 infections but also against HSV-2 and VZV infections. There may be appreciable quantitative differences between the rates of metabolism of penciclovir in HSV-and VZVinfected cells. The uptake and phosphorylation in VZVinfected cells has been reported for a pyrimidine analog, 1-3-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (25) , and for acyclovir at 250 ,uM (1), but we are unaware of any reports of similar work with acycloguanosine analogs at clinically relevant concentrations. Only recently (2) have we been able to provide a clear indication that penciclovir has prolonged antiviral activity in VZV-infected cells. Therefore, it was of particular interest to determine whether penciclovir-triphosphate (PCV-TP) is formed and then remains at high concentrations within VZV-infected cells following treatment of the cell culture for a short period.
Penciclovir, through its triphosphate ester ( Fig. 1) , is a potent and selective antiherpesvirus agent, particularly against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2, respectively) and varicella-zoster virus (VZV) (9, 3, 4) . Previous studies (3, 4, 9) showed that penciclovir has a spectrum of antiviral activity similar to that of acyclovir, but that penciclovir has an antiviral effect that is longer lasting than that of acyclovir. This may relate to the efficient trapping of the active metabolite, the triphosphate ester of penciclovir, within virus-infected cells (22) . Penciclovir and its well-absorbed oral form, famciclovir (23) , are undergoing clinical trials for their efficacies not only against HSV-1 infections but also against HSV-2 and VZV infections. There may be appreciable quantitative differences between the rates of metabolism of penciclovir in HSV-and VZVinfected cells. The uptake and phosphorylation in VZVinfected cells has been reported for a pyrimidine analog, 1-3-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (25) , and for acyclovir at 250 ,uM (1), but we are unaware of any reports of similar work with acycloguanosine analogs at clinically relevant concentrations. Only recently (2) have we been able to provide a clear indication that penciclovir has prolonged antiviral activity in VZV-infected cells. Therefore, it was of particular interest to determine whether penciclovir-triphosphate (PCV-TP) is formed and then remains at high concentrations within VZV-infected cells following treatment of the cell culture for a short period.
In this report, we describe the continuation of our studies For phosphorylation experiments, MRC-5 cells were grown to near confluency under normal conditions (2medium supplemented with 10% fetal calf serum) in 25-cm flasks; the medium was then poured off and the monolayer was infected with cell-associated virus in fresh medium (10 ml, 2% newborn calf serum 1% penicillin-streptomycin). Infections were allowed to proceed for a minimum of 48 h, at which point the first signs of a cytopathic effect became visible.
Once the desired extent of the cytopathic effect was reached, cell monolayers were incubated with fresh maintenance medium (3 ml) containing 10 pM [3H]penciclovir or [3HIacyclovir (each at 28 GBq/mmol). At appropriate times after acyclonucleoside addition, intracellular phosphates were extracted as described previously (22) . The stability of PCV-TP was studied by adding fresh maint-enance medium (3 ml) containing 10 ,uM [3H]penciclovir (28 GBq/mmol) approximately 100 h after infection, incubating for a further 18 h before removal, and replenishing with fresh medium (50 ml). Harvesting of the remaining intracellular phosphates, at the times indicated in the Results, was as described above for HSV-2 infected cells. HPLC 6 .8], 6% methanol). Flow rates of 0.5 mI/mi were used for elution in both HPLC methods; the tritiated nucleosides and nucleotides were monitored with an ISOFLO detector and peak areas calculated by using either an Apple computer and a Nuclear Enterprises Ltd. program or a Walters PC AT computer and RAYTEST RAMONA Radio-Chromatographic system program. Concentrations of nucleosides and phosphate esters were calculated from the corresponding peak areas of [3H]acyclonucleoside standards chromatographed under identical conditions. All other equipment and methodologies were as described previously (22) , with the additional use of an LKB 2156 solvent conditioner.
DNA polymerase preparations. The following procedures were carried out at 4°C. HSV-1 and HSV-2 DNA polymerases were extracted from infected MRC-5 cells (multiplicity of infection, 0.01 PFU per cell, incubated for 40 h at 37°C) by treatment with high salt concentrations essentially as described previously (17) . After dialysis versus buffer C (50 mM HEPES [N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid; pH 7.8; 0.1 mM EDTA;0.1 mMdithiothreitol; 20% [vol/vol] glycerol; protease inhibitors pepstatin A, leupeptin, soybean trypsin inhibitor [each at 0.5 ,g/ml]), DNA polymerase extracts were chromatographed on a DEAESepharose column. Fractions containing DNA polymerase activity were pooled and then frozen at -40°C until they were required for Ki determinations. VZV DNA polymerase from infected cultures showing a cytopathic effect of about 80% was prepared as described above, except that the extract was chromatographed on a phosphocellulose column. MRC-5 cell DNA polymerase a from uninfected cells was purified by DEAE-Sepharose chromatography. In order to perform DNA chain elongation assays, HSV-2 and MRC-5 DNA polymerases needed further purification to remove contaminating DNase activity. HSV-2 DNA polymerase was chromatographed on a Whatman Pll phosphocellulose column; the later part of the DNA polymerase peak (fraction 2) was nuclease-free. MRC-5 DNA polymerase a was further purified on an anti-DNA polymerase immunoglobulin G-agarose column (modified from a previously described method [15] Research Laboratories). The viral DNA content was then determined by hybridization with a 32P-labeled probe specific for HSV-2 DNA essentially as described previously (6) . The HSV-2 DNA probe pGR60 contains the HSV-2 BglII N fragment cloned in pBR322 (provided by P. O'Hare, Marie Curie Memorial Foundation, Oxted, United Kingdom). Phosphorylation of penciclovir and acyclovir in HSV-2-infected cells. Both penciclovir and acyclovir were phosphorylated to the triphosphate ester in HSV-2-infected MRC-5 cells. However, the rate of phosphorylation of penciclovir was much greater than that of acyclovir ( concentrations, the loss of compound in the medium was balanced by the increased amount of phosphorylated compound in the cells. Because the amount of drug in the cell culture medium was reduced during the incubation to about 40 to 50% of its initial value, this could easily account for the slight reduction in the observed phosphorylation rate.
ACV-TP was also formed in increasing concentrations over the 24-h incubation, although the initial rate of formation during the first 2 h was much more than that during the (Fig. 3a) . In contrast, the concentrations of the phosphates of acyclovir decreased much more rapidly, falling below the detection limit within 4 h (Fig. 3b) . Under these conditions, the half-lives of the triphosphates of penciclovir and acyclovir were about 20 and 1 h, respectively. As the amounts of acyclonucleotides within the cells decreased, the resulting acyclonucleoside diffused out of the cells into the culture medium. In cell cultures treated with penciclovir, the concentrations of penciclovir in the medium increased almost linearly during the 8-h incubation period (Fig. 3c) . In contrast, acyclovir concentrations initially increased rapidly but reached the maimum level after 2 h (Fig. 3d) , by which time virtually all of the acyclovir phosphates had been converted to acyclovir.
Penciclovir and acyclovir phosphate formation in VZVinfected ceQls. Initial experiments found that, early in the cell culture infection while the cytopathic effect was low, rates of PCV-TP formation were limited by the number of cells infected with VZV. Having determined suitable conditions for the study of phosphate formation, more comprehensive 6-h time course experiments were undertaken (Fig. 4) . PCV-TP formation was nearly linear with time. At 6 h after the addition of penciclovir to a cell monolayer with a cytopathic effect of approximately 80%, the concentration of PCV-TP was 220 pmolI106 cells. We were unable to detect ACV-TP, even after incubation with acyclovir for 6 h in a cell monolayer with a cytopathic effect of 80%; under these conditions, the limit of detection was estimated to be 1 pmolI106 cells, inferring that ACV-TP levels were <0.25 ,uM. As in both HSV-1-and HSV-2-infected MRC-5 cells, penciclovir appears to be phosphorylated much more readily than acyclovir in VZV-infected cells, implying that the former is a better substrate for HSV-and VZV-encoded thymidine kinases. At the end of this experiment, the approximate ratio of the mono-, di-, and triphosphates were 1:5:10, respectively (Fig. 4, inset) .
Stability of PCV-TP in VZV-infected cells. To ensure that sufficient concentrations of PCV-TP were formed for subsequent stability analysis, infected cell monolayers were incubated for 4 days, by which time an extensive cytopathic effect had developed, before incubating overnight with 10 j.4M penciclovir. The intracellular PCV-TP stability profile is depicted in Fig. 5 , and from the line fitted by linear regression, a half-life of 7.2 h was derived. However, approximately 30% of the initial intracellular PCV-TP concentration was still present 24 h after drug removal.
Inhibition of isolated DNA polymerases. We determined previously (11) that, following HSV-1 infection of MRC-5 cells and incubation with penciclovir, >95% of the triphosphate ester of penciclovir formed is the (S) enantiomer. (S)-PCV-TP was synthesized biochemically via this route and was purified as described in Materials and Methods; a chemically synthesized racemate of PCV-TP was purified for these studies to give an indication of the inhibitory effect of the (R) enantiomer of PCV-TP. The data from representative kinetic experiments are presented as Lineweaver-Burk plots (Fig. 6) DNA chain extension assays. By using the dideoxy DNA sequencing methodology with saturating concentrations of all four normal dNTPs, both MRC-5 and HSV-2 DNA polymerases were able to extend the primer hybridized to M13 DNA template, with the herpesvirus polymerase being more processive than DNA polymerase a (Fig. 7, lanes 1 and   6 ). In the absence of dGTP (Fig. 7, lanes 5 and 10) , a small amount of misincorporation of the other three natural dNTPs was observed; HSV-2 DNA polymerase displayed a reduced fidelity of replication compared with DNA polymerase a. DNA polymerase assays in the presence of ACV-TP (Fig. 7 , lanes 4 and 9) indicated that ACV-TP is readily incorporated into DNA at the first position where dGTP would normally be inserted, resulting in chain termination. PCV-TP did allow limited DNA chain extension past several presumed penciclovir-monophosphate residues (Fig. 7, lanes 2 and 7) , whereas ACV-TP terminated DNA chain extension (Fig. 7,  lanes 4 and 9) . Inclusion of (R,S)-PCV-TP in DNA chain extension assays resulted in a marked decrease in DNA synthesis (Fig. 7, lanes 3 and 8) in comparison with (S)-PCV-TP, suggesting that the (R) enantiomer is a poorer substrate than the (S) enantiomer for both DNA polymerases.
The effects of (S)-PCV-TP on the incorporation of the other nucleotides were studied by using a short defined 17:26-mer primer-template: 
'-TGTGAAATTGTTATCCG-3 '
This primer-template could be extended by up to nine bases, three each of dATP, dCTP, and dTTP. Because there was no 0 0 o= position at which dGTP would normally be inserted, the c) E effect of (S)-PCV-TP on the incorporation of these other 0. E three dNTPs could be studied without hindrance from the 10 PCV-DP competitive inhibition and any possible inactivation processes that would occur with the M13 DNA template. There was no effect on the incorporation of dATP or dCTP by (S)-PCV-TP, but into DNA compared with ACV-TP. Inhibition by (S)-PCV-TP under processive and nonprocessive conditions. An assay method was developed in order to size and quantitate DNA products up to 7.3 kb in length; this is the maximum length that would be obtained if the M13 positive-strand DNA was replicated completely by highly processive DNA polymerase action. DNA synthesis was quantitated by determining [32pJdATP incorporation into DNA; the sizes of the synthesized DNA strands were estimated from autoradiographs of denaturing agarose gels. It had been reported previously (16) that the processivity of pure HSV-1 DNA polymerase is greatly enhanced by the addition of Eschericllia coli single-strand DNA-binding protein. This effect was not observed with our partially purified viral DNA polymerase samples, possibly because they would have contained the viral protein encoded by the gene UIL42 (7) . The processivity of our HSV-2 DNA polymerase was, however, sensitive to the assay incubation temperature. DNA of almost 7 kb was synthesized at a temperature of 320C, but only short lengths (<0.5 kb) were synthesized at 37 or 30~'C. Having established the optimum conditions for processive DNA replication, dose-response curves for (S)-PCV-TP (Fig. 8) and (R,S)-PCV-TP were determined with 12 pM dGTP; this is about the level detected in acyclovirtreated HSV-infected human fibroblast ceils (12) . The IC50s were calculated to be 176 ±-8 and approxiimately 310 RaM, respectively. The ratio of IC50s for (S)-and (R,S)-PCV-TPs (1:1.8) closely parallels the corresponding ratio of K~s for competitive ihiMbition with respect to dGTP (1:1.6), inferring that the inhibitory effectiveness of each enantiomer is probably directly related to its ability to compete with dGTP.
Under nonprocessive replication conditions, inhibition of chain elongation by (S)-PCV-TP was not detected, confirming the observations of other workers (14) that drug activity is dependent upon polymerase processivity.
Effect of short treatment time of cells on inhibition of HSV-2 DNA synthesis. In a conventional dose-response test, in which penciclovir and acyclovir were present continuously in the cell culture medium, both compounds were almost equally active (IC50s, 0.05 and 0.04 I.gOml, respectively). To .x e the effect of short treatment times, compounds were added at 5 h postinfection, by which time the viral thymidine kinase should have been produced; however, this was before the start of the viral DNA synthesis at 8 h after infection. The compounds were removed at various times (b) . At 24 h after infection, cell-associated HSV-2 DNA was measured by hybridization with the 32P-labeled DNA probe pGR60. Each point represents the mean ± standard deviation of four replicate observations. Levels of HSV-2 DNA in cultures treated for 1.5 h were not significantly different from those in the untreated virus control cultures when penciclovir was present at 1 jLM or acyclovir was present at either 1 or 3 pM (P > 0.05).
thereafter and replaced with drug-free medium. Levels of viral DNA were determined at 24 h postinfection by hybridization with a DNA probe specific for HSV-2. For comparison, control cultures were treated continuously from 1 to 24 h after infection.
Whereas 1 h of treatment of HSV-2-infected cells with penciclovir resulted in a slight inhibition of viral DNA synthesis, treatment for 1.5 h demonstrated the more effective inhibition of viral DNA synthesis by penciclovir than by acyclovir (Fig. 9 ). Significantly (P = 0.001) reduced levels of viral DNA were present in cells treated with 3 and 10 ,uM penciclovir for 1.5 h compared with the levels in cells similarly treated with acyclovir. In contrast, following continuous treatment from 1 h after infection, both compounds gave good inhibition of viral DNA synthesis.
Our initial studies (22) with HSV-1-infected cells indicated that penciclovir is phosphorylated to give high concentrations of the triphosphate ester in infected cells, but not in uninfected cells. This triphosphate of penciclovir was much more stable than that of acyclovir, the half-lives being 10 and 0.7 h, respectively. We extended these studies to include HSV-2-and VZV-infected cells. As in the previous study (22) , the experimental conditions were chosen to be as relevant as possible to the clinical situation. We used human fibroblast cells (MRC-5) and penciclovir concentrations (l10 ,uM) which are achieved in humans following either intravenous administration of penciclovir (5) or oral administration of famciclovir (24) .
In HSV-2-infected cells, the phosphorylation of penciclovir was comparable to that in HSV-1-infected cells, but there were some small differences. The proportions of the monoand diphosphate esters, relative to the proportion of the triphosphate ester, were slightly lower in the cells infected with HSV-2 than in the corresponding cells infected with HSV-1 and were again low in the experiment that compared penciclovir and the phosphorylation of acyclovir in HSV-2 infected cells. This may be due to a small difference in the activities of the thymidine kinases encoded by HSV-1 and HSV-2. However, the rates of formation of PCV-TP in HSV-2-infected cells treated with 1 or 10 ,uM penciclovir ( Fig. 2) were similar to those found in HSV-1-infected cells (22) .
Although we did not compare directly the phosphorylation of acyclovir in HSV-1-and HSV-2-infected cells within the same experiment, we did obtain much higher concentrations of ACV-TP with HSV-2 in this study than we did previously with HSV-1 (22) . Despite an overall increased rate of phosphorylation, the levels of acyclovir-monophosphate were markedly lower than those of ACV-TP except at the earliest time points, whereas in HSV-1-infected cells, the mono-and triphosphates were present at about equal concentrations. In contrast to penciclovir, which was phosphorylated at an almost linear rate throughout the incubation, ACV-TP was formed much more slowly after the first 2 h of the incubation (Fig. 2) . After 4 h of incubation in HSV-2-infected cells, the concentration of PCV-TP was about 15-fold that of ACV-TP, but this ratio was not as high, about 100-fold, as that found previously (22) in HSV-1-infected cells.
In uninfected cells, we were usually unable to detect the phosphates of penciclovir or acyclovir. However, in the control uninfected cells for experiments with HSV-2, low levels of the triphosphates were detected. With both penciclovir and acyclovir, the amount of triphosphate ester was about 1 to 2 pmol/106 cells at 4 h and then remained at about this level for the rest of the 24 h of incubation. Tolman (21) has indicated that it is more desirable for an acyclonucleoside to be poorly converted to a triphosphate which is an efficient inhibitor of viral replication (e.g., acyclovir) than to one which is efficiently converted to triphosphate. Efficient phosphorylation by virus-specified kinases means more phosphorylation (although orders of magnitude less) by host cell kinases in an uninfected cell. Although this may seem to be a reasonable expectation, our work has shown that this prediction does not apply to penciclovir. Penciclovir is phosphorylated much more efficiently than acyclovir in herpesvirus-infected cells, but the host cell kinases phosphorylate the two compounds to a small but comparable extent. This highly preferential metabolism of penciclovir in VOL. 36, 1992 herpesvirus-infected cells is a major factor in its selective antiviral activity.
When it was found that penciclovir was phosphorylated in In VZV-infected cells, the rate of formation of PCV-TP increased as the infection proceeded, but even late in the infection, this rate was nearly 10-fold less than those in celis infected with either HSV-1 or HSV-2. This may be due, at least in part, to the slow progression of VZV infection in cell culture. However, the concentration of PCV-TP was at least 30-fold greater than that of ACV-TP, which remained below the limit of detection. The very low level of ACV-TP was to be expected from the work of Biron and Elion (1), who reported that 250 FLM acyclovir is converted to the triphosphate ester (about 10 to 35 pmol106 cells). Although the IC50 of PCV-TP was greater than that of ACV-TP, this was compensated for by the high levels of PCV-TP formed in VZV-infected cells.
The confirmation that PCV-TP inhibits herpesvirus DNA polymerases gives support to our view (22) that the entrapment of PCV-TP at high concentrations within virus-infected cells and the stability of PCV-TP accounted for the good antiviral activity against HSV-1. We showed that in HSV-2-infected cells PCV-TP is much more stable than ACV-TP, the half-lives being 20 and 1 h, respectively. Furthermore, just as we have shown good activity with penciclovir after treating HSV-1-infected cells for a short time (22) , we did a similar experiment with HSV-2-infected cultures. As before, we used concentrations of penciclovir which have been achieved in plasma following oral administration of famciclovir (1,000 mg, 3.1 mmol) to healthy subjects (24) . Plasma penciclovir concentrations that exceeded 10 p,M (2.5 p,g/ml) lasted for about 1.5 h. In contrast, after an oral dose of acyclovir (800 mg, 3.6 mmol), the maxmum peak levels of acyclovir in blood were only about 7.5 pM (13). This assay with short treatment times (1.5 h) therefore represents the clinical conditions following oral dosing more closely than does the standard antiviral assay in which the compounds are present continuously at set concentrations. Whereas 3 pM acyclovir was inactive after 1.5 h of incubation (Fig. 9) , penciclovir was signiicantly (P = 0.001) active at those concentrations (3 and 10 pM) which have been achieved in huans.
In VZV-infected cells, PCV-TP had good stability, the half-life being over 7 h (Fig. 5) antiviral activity of penciclovir. In the corresponding clinical infections, PCV-TP would be expected to remain trapped within the infected cells even when the concentration of penciclovir in the blood drops to low levels. Thus, it should be possible to treat each of these herpesvirus infections with famciclovir, the oral form of penciclovir, at a lower dosage frequency than is required for acyclovir.
